Iovance Biotherapeutics, Inc. (IOVA)

Iovance Biotherapeutics Stock Forecast

Stock Price Forecast

The 9 analysts that cover Iovance Biotherapeutics stock have a consensus rating of "Buy" and an average price target of $9.00, which forecasts a 166.27% increase in the stock price over the next year. The lowest target is $4.00 and the highest is $16.

Price Target: $9.00 (+166.27%)

Analyst Consensus: Buy

Target	Low	Average	Median	High
Price	$4.00	$9.00	$9.00	$16
Change	+18.34%	+166.27%	+166.27%	+373.37%

Analyst Ratings

The average analyst rating for Iovance Biotherapeutics stock is "Buy". This means that analysts believe this stock is likely to outperform the market over the next twelve months.

Recommendation Trends

Rating	Nov '25	Dec '25	Jan '26	Feb '26	Mar '26	Apr '26
Strong Buy	4	4	4	4	3	3
Buy	5	5	5	6	5	5
Hold	3	3	3	3	2	2
Sell	0	0	0	0	0	0
Strong Sell	0	0	0	0	0	0
Total	12	12	12	13	10	10

Latest Forecasts

Analyst	Firm	Rating	Rating	Action	Price Target	Upside	Date
Geulah Livshits Chardan Capital	Chardan Capital	Strong Buy Maintains $16	Strong Buy	Maintains	$16	+373.37%	Apr 10, 2026
David Dai UBS	UBS	Hold Maintains $2 → $4	Hold	Maintains	$2 → $4	+18.34%	Mar 5, 2026
Reni J. Benjamin Citizens	Citizens	Hold → Buy Upgrades $5	Hold → Buy	Upgrades	$5	+47.93%	Mar 3, 2026
Etzer Darout Barclays	Barclays	Buy Maintains $10 → $11	Buy	Maintains	$10 → $11	+225.44%	Feb 25, 2026
Reni J. Benjamin Citizens	Citizens	Hold → Buy Upgrades $5	Hold → Buy	Upgrades	$5	+47.93%	Feb 25, 2026

More Analyst Ratings

Financial Forecast

Revenue This Year

389.29M

Increased by 47.74%

from 263.50M

Revenue Next Year

546.21M

Increased by 40.31%

from 389.29M

EPS This Year

-0.50

from -1.09

EPS Next Year

-0.22

from -0.50

Fiscal Year	FY 2021	FY 2022	FY 2023	FY 2024	FY 2025	FY 2026	FY 2027
Period Ending	Dec 31, 2021	Dec 31, 2022	Dec 31, 2023	Dec 31, 2024	Dec 31, 2025	Dec 31, 2026	Dec 31, 2027
Revenue	-	-	1.19M	164.07M	263.50M	389.29M	546.21M
Revenue Growth	-	-	-	13,698.99%	60.60%	47.74%	40.31%
EPS	-2.23	-2.49	-1.89	-1.28	-1.09	-0.50	-0.22
EPS Growth	-	-	-	-	-	-	-
Forward PE	-	-	-	-	-	-	-
No. Analysts	-	-	-	-	-	13	12

Historical EPS numbers are GAAP, while forecasted numbers may be non-GAAP.

Revenue Forecast

Revenue	2026	2027	2028	2029	2030	2031	2032	2033
High	451.5M	732.8M
Avg	389.3M	546.2M
Low	341.0M	431.2M

Revenue Growth

Revenue Growth	2026	2027	2028	2029	2030	2031	2032	2033
High	71.3%	88.2%
Avg	47.7%	40.3%
Low	29.4%	10.8%

EPS Forecast

EPS	2026	2027	2028	2029	2030	2031	2032	2033
High	-0.28	-0.04
Avg	-0.50	-0.22
Low	-0.64	-0.38

EPS Growth

EPS Growth	2026	2027	2028	2029	2030	2031	2032	2033
High	-	-
Avg	-	-
Low	-	-

Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.